,58 Nevertheless, the identification of CACNA1I gain-of-function mutations to be causative for a range of neurodevelopmental phenotypes, including difficult-to-treat epilepsy, makes Cav3.3 an attractive target for pharmacological treatment with licensed T-type channel blockers, as well as for the development of new Cav3.3-specific inhibitors.7 This evidence concerns the gene CACNA1I and epilepsy.